Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women

被引：6
作者：
Oishi A. [1 ]
Mochizuki Y. [1 ]
Otsu R. [1 ]
Inaba N. [1 ]
机构：
[1] Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Mibu, Tochigi
来源：
BioPsychoSocial Medicine | / 1卷 / 1期
关键词：
Depressive Symptom; Hormone Replacement Therapy; Fluvoxamine; Postpartum Depression; Vasomotor Symptom;
D O I：
10.1186/1751-0759-1-12
中图分类号：
学科分类号：
摘要：
Background: Selective serotonin-reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression and can be used as nonhormonal alternatives to manage hot flashes for women with a history of breast cancer and unable to take hormone replacement therapy. There are, however, few reports on the efficacy of SSRIs for the treatment of natural postmenopausal climacteric symptoms. In this pilot study, we evaluate the SSRI, fluvoxamine, for controlling climacteric symptoms and vasomotor symptoms, in particular. Methods: Twenty-two patients were enrolled from our hospital. All were orally administered fluvoxamine (50 mg daily). Climacteric and depressive symptoms were assessed using simple menopausal index (SMI) and self-rating questionnaire for depression (SRQ-D), respectively, at baseline, and at 2 and 6 weeks post-treatment. Results: Six weeks following drug administration, neither the SRQ-D nor SMI scores significantly decreased compared to baseline. The mean levels of vasomotor symptoms and mental symptoms decreased significantly following fluvoxamine administration, while skeletal muscle symptom scores did not. Conclusion: We were able to demonstrate that fluvoxamine was effective in treating not only depressive moods in climacteric symptoms but also the associated vasomotor symptoms. There are several limitations to this preliminary study. Future controlled studies are needed to further evaluate the efficacy of fluvoxamine for climacteric disturbances. © 2007 Oishi et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
  • [1] Greendale G.A., Lee N.P., Arriola E.R., The menopause, Lancet, 353, pp. 571-580, (1999)
  • [2] Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial, JAMA, 88, pp. 321-333, (2002)
  • [3] Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., Bonds D., Brunner R., Brzyski R., Caan B., Chlebowski R., Curb D., Gass M., Hays J., Heiss G., Hendrix S., Howard B.V., Hsia J., Hubbell A., Jackson R., Johnson K.C., Judd H., Kotchen J.M., Kuller L., LaCroix A.Z., Lane D., Langer R.D., Lasser N., Lewis C.E., Manson J., Margolis K., Ockene J., O'Sullivan M.J., Phillips L., Prentice R.L., Ritenbaugh C., Robbins J., Rossouw J.E., Sarto G., Stefanick M.L., Van Horn L.,
  • [4] Gonzales G.F., Carillo C., Blood serotonin levels in postmenopausal women
  • [5] effect of age and serum oestradiol therapy levels, Maturitas, 17, pp. 23-29, (1993)
  • [6] Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., Halyard M.Y., Pruthi S., Novothy P.J., Rummans T.A., Phase III evaluation of fluoxetine for treatment of hot flashes, J Clin Oncol, 20, pp. 1578-1583, (2002)
  • [7] Stearns V., Isaacs C., Rowland J., Crawford J., Ellis M.J., Kramer R., Lawrence W., Hanfelt J.J., Hayes D.F., A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors, ANN ONCOL, 11, pp. 17-22, (2000)
  • [8] Stearns V., Beebe K.L., Iyengar M., Dube E., Paroxetine controlled release in the treatment of menopausal hot flashes, JAMA, 289, pp. 2827-2834, (2003)
  • [9] Suri R., Burt V.K., Altshuler L.L., Zuckerbrow-Miller J., Fairbanks L., Fluvoxamine for postpartum depression, Am J Psychiatry, 158, pp. 1739-1740, (2001)
  • [10] Zung W.W.K., A self-rating depression scale, Arch Gen Psychiatry, 12, pp. 63-70, (1965)
123